Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis|Lastest “Digestive” News

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis
Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis, which will evaluate Intercept’s first-in-class farnesoid X receptor agonist obeticholic acid as a novel therapy for NASH.
Read more on News-Medical-Net

Posts Related to Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis|Lastest “Digestive” News